Stay updated on Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page revision tag was updated from v3.6.2 to v3.6.3, indicating a maintenance update. No visible study details or functionality appear to be altered.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page revision label was updated from v3.6.0 to v3.6.2, indicating a small update to the page software or documentation. No study content or user-facing information was altered.SummaryDifference0.1%

- Check35 days agoChange DetectedAdded new navigation/help sections—How to Read a Study Record, Common Questions, and How to Join a Study—and a recruitment note stating No longer looking for participants. The Intervention / Treatment heading was normalized to Intervention/Treatment and the page revision stamp updated to v3.6.0.SummaryDifference0.4%

- Check42 days agoChange DetectedRevision: v3.5.5 indicates a minor page update. It does not change the clinical trial data, eligibility criteria, or how the page is used.SummaryDifference0.1%

- Check63 days agoChange Detected- Revision indicator updated from v3.5.3 to v3.5.4, reflecting a new build of the page.SummaryDifference0.1%

- Check84 days agoChange DetectedThe site’s release/version indicator for the ClinicalTrials.gov study page has been updated from v3.5.2 to v3.5.3, reflecting a platform or content release change rather than any modification to the study details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Sunitinib in Thymic Cancer Clinical Trial page.